Amferia’s proprietary technology is a new and effective antimicrobial material that targets and rapidly kills bacteria upon contact, including numerous antibiotic resistant bacteria like MRSA and MDR E. Coli. The material is highly selective and targets bacteria while being entirely non-toxic to human and animal cells. Today, the team has transformed this concept into a technology platform, with the first product being a antibacterial wound care dressing for skin wound applications supported by strong scientific and clinical evidence.
Amferia was founded in 2018 as a spin-off from Chalmers University, Sweden.
Watch Saba Atefyekta, one of the founders of Amferia, present the company in the video below: